PRISM BioLab Co.,LTD
206A.T · JPX
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.23 | -0.10 | 0.05 | 0.00 |
| FCF Yield | -24.98% | -0.48% | -2.73% | 0.48% |
| EV / EBITDA | -3.88 | -8.05 | -38.89 | 271.45 |
| Quality | ||||
| ROIC | -28.60% | -22.33% | -43.37% | 3.92% |
| Gross Margin | 39.83% | 52.53% | 71.11% | 96.53% |
| Cash Conversion Ratio | 1.76 | -0.14 | 0.98 | 1.41 |
| Growth | ||||
| Revenue 3-Year CAGR | 81.69% | -18.01% | 4,833,432.56% | 8,214,883.51% |
| Free Cash Flow Growth | -2,390.63% | 88.78% | -663.94% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 3.51 | 4.19 | 2.32 | -24.86 |
| Interest Coverage | 0.00 | -57.97 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -42.03 | -79.55 | -301.86 | -517.76 |